China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China This marks the first approval of pamiparib and the third BeiGene-discovered medicine to receive regulatory approval...

Full "IntellAsia: Resources" article